# Tonix Pharmaceuticals (TNXP) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/TNXP
## Company Profile
- Ticker: TNXP
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 11.97 USD
- Market cap: 186826187.72 USD
- Last updated: 2026-08-12
## Business Overview
### Commercial Fibromyalgia Franchise
Tonix Pharmaceuticals is a commercial-stage biopharmaceutical company centered on TONMYA, a bedtime treatment for fibromyalgia. The product is intended to address nonrestorative sleep and other core features of the disease and represents the company's principal commercial franchise.
### Infectious-Disease Pipeline
Beyond its commercial business, Tonix is developing TNX-4800, a long-acting human monoclonal antibody designed to prevent Lyme disease by targeting outer surface protein A on *Borrelia burgdorferi*.
### Broader Development Platform
The company also maintains mid-stage and earlier-stage programs spanning immunology, infectious diseases and central nervous system disorders, giving it a mixed commercial-and-development-stage operating profile.
## Why The Stock Is Moving

As of Aug 12, 2026, TNXP closed down 3.00% at $11.97. No new same-company headline was identified in the current news window.

## Future Catalysts

- FDA meeting in 2026 to inform the design of the next Phase 2 study of TNX-1300 for cocaine intoxication.
- Initiation of the adaptive Phase 2 U.S. field study of TNX-4800 for Lyme-disease prevention in the first quarter of 2027, pending final FDA agreement.
- Topline data from the investigator-sponsored OASIS study of TNX-102 SL in acute stress reaction in mid-2027.

## Drug Assets

- TNX-102

## Recent News
- 2026-08-10 11:00 EST — [Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights](https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-reports-second-quarter-2026-financial-results-and-operatio-bab26d3b) — Source: Tonix Pharmaceuticals
- 2026-08-05 11:00 EST — [Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-to-participate-in-upcoming-investor-conferences-47f5fb2d) — Source: Tonix Pharmaceuticals
- 2026-08-03 11:00 EST — [Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.](https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-positive-minutes-from-type-c-fda-meeting-to-disc-cea2cde0) — Source: Tonix Pharmaceuticals
- 2026-07-27 11:00 EST — [Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-august--7e18d9ce) — Source: Tonix Pharmaceuticals
- 2026-07-15 13:05 EST — [Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models](https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-publication-in-the-peer-reviewed-journal-of-viro-14c8c277) — Source: Tonix Pharmaceuticals